Skip to main content
SpringerLink
Log in

Polymorphisms in the promoter region of estrogen receptor β gene in endometrial cancer

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Introduction

The development of endometrial cancer is known to be affected by estrogens. Thus, genetic variations like single nucleotide polymorphisms (SNPs) in genes involved in estrogen biosynthesis, metabolism, and signal transduction might affect risk for endometrial cancer. In this study, we tested the hypothesis that polymorphisms in the promoter of ESR2 gene may be associated with susceptibility to this disease.

Methods

We compared the frequency of three SNPs in the promoter region of ESR2 gene (rs2987983, rs3020450, and rs3020449) in 135 women with endometrial cancer and 135 healthy women serving as controls by means of allele-specific tetra-primer PCR.

Results

Regarding allele frequency, allele positivity or genotype frequencies of these SNPs we did not observe any significant difference between healthy women and women with endometrial cancer.

Conclusion

Our data clearly suggest that the tested SNPs in the promotor region of human ESR2 gene are not associated with the development of endometrial cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Sorosky JI (2008) Endometrial cancer. Obstet Gynecol 111(2 Pt 1):436–447. doi:10.1097/AOG.0b013e318162f690

    Article  PubMed  Google Scholar 

  2. Ito K, Utsunomiya H, Yaegashi N, Sasano H (2007) Biological roles of estrogen and progesterone in human endometrial carcinoma—new developments in potential endocrine therapy for endometrial cancer. Endocr J 54(5):667–679

    Article  CAS  PubMed  Google Scholar 

  3. Gustafsson JA (1997) Estrogen receptor beta—getting in on the action? Nat Med 3(5):493–494

    Article  CAS  PubMed  Google Scholar 

  4. Skrzypczak M, Bieche I, Szymczak S, Tozlu S, Lewandowski S, Girault I, Radwanska K, Szczylik C, Jakowicki JA, Lidereau R, Kaczmarek L (2004) Evaluation of mRNA expression of estrogen receptor beta and its isoforms in human normal and neoplastic endometrium. Int J Cancer 110(6):783–787. doi:10.1002/ijc.20224

    Article  CAS  PubMed  Google Scholar 

  5. Collins F, MacPherson S, Brown P, Bombail V, Williams AR, Anderson RA, Jabbour HN, Saunders PT (2009) Expression of oestrogen receptors, ERalpha, ERbeta, and ERbeta variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERalpha. BMC Cancer 9:330

    Article  PubMed Central  PubMed  Google Scholar 

  6. Haring J, Skrzypczak M, Stegerer A, Lattrich C, Weber F, Gorse R, Ortmann O, Treeck O (2012) Estrogen receptor beta transcript variants associate with oncogene expression in endometrial cancer. Int J Mol Med 29(6):1127–1136. doi:10.3892/ijmm.2012.929

    PubMed  Google Scholar 

  7. Erfani N, Razmkhah M, Talei AR, Pezeshki AM, Doroudchi M, Monabati A, Ghaderi A (2006) Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet Cytogenet 165(2):114–120. doi:10.1016/j.cancergencyto.2005.07.020

    Article  CAS  PubMed  Google Scholar 

  8. Harendza S, Lovett DH, Panzer U, Lukacs Z, Kuhnl P, Stahl RA (2003) Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem 278(23):20490–20499. doi:10.1074/jbc.M211536200

    Article  CAS  PubMed  Google Scholar 

  9. Yang Q, Nakamura M, Nakamura Y, Yoshimura G, Suzuma T, Umemura T, Tamaki T, Mori I, Sakurai T, Kakudo K (2002) Correlation of prostate-specific antigen promoter polymorphisms with clinicopathological characteristics in breast cancer. Anticancer Res 22(3):1825–1828

    CAS  PubMed  Google Scholar 

  10. Greenlee H, Chen Y, Kabat GC, Wang Q, Kibriya MG, Gurvich I, Sepkovic DW, Bradlow HL, Senie RT, Santella RM, Ahsan H (2007) Variants in estrogen metabolism and biosynthesis genes and urinary estrogen metabolites in women with a family history of breast cancer. Breast Cancer Res Treat 102(1):111–117. doi:10.1007/s10549-006-9308-7

    Article  CAS  PubMed  Google Scholar 

  11. Crooke PS, Ritchie MD, Hachey DL, Dawling S, Roodi N, Parl FF (2006) Estrogens, enzyme variants, and breast cancer: a risk model. Cancer Epidemiol Biomark Prev 15(9):1620–1629. doi:10.1158/1055-9965.EPI-06-0198 (A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology)

    Article  CAS  Google Scholar 

  12. Zheng SL, Zheng W, Chang BL, Shu XO, Cai Q, Yu H, Dai Q, Xu J, Gao YT (2003) Joint effect of estrogen receptor beta sequence variants and endogenous estrogen exposure on breast cancer risk in Chinese women. Cancer Res 63(22):7624–7629

    CAS  PubMed  Google Scholar 

  13. Schuit SC, de Jong FH, Stolk L, Koek WN, van Meurs JB, Schoofs MW, Zillikens MC, Hofman A, van Leeuwen JP, Pols HA, Uitterlinden AG (2005) Estrogen receptor alpha gene polymorphisms are associated with estradiol levels in postmenopausal women. Eur J Endocrinol 153(2):327–334. doi:10.1530/eje.1.01973

    Article  CAS  PubMed  Google Scholar 

  14. Tempfer CB, Schneeberger C, Huber JC (2004) Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology. Pharmacogenomics 5(1):57–65. doi:10.1517/phgs.5.1.57.25687

    Article  CAS  PubMed  Google Scholar 

  15. Gold B, Kalush F, Bergeron J, Scott K, Mitra N, Wilson K, Ellis N, Huang H, Chen M, Lippert R, Halldorsson BV, Woodworth B, White T, Clark AG, Parl FF, Broder S, Dean M, Offit K (2004) Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res 64(24):8891–8900. doi:10.1158/0008-5472.CAN-04-1256

    Article  CAS  PubMed  Google Scholar 

  16. Ye S, Dhillon S, Ke X, Collins AR, Day IN (2001) An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res 29(17):E88

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Cribb AE, Knight MJ, Dryer D, Guernsey J, Hender K, Tesch M, Saleh TM (2006) Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomark Prev 15(3):551–558. doi:10.1158/1055-9965.EPI-05-0801 (A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology)

    Article  CAS  Google Scholar 

  18. Treeck O, Elemenler E, Kriener C, Horn F, Springwald A, Hartmann A, Ortmann O (2009) Polymorphisms in the promoter region of ESR2 gene and breast cancer susceptibility. J Steroid Biochem Mol Biol 114(3–5):207–211. doi:10.1016/j.jsbmb.2009.02.012

    Article  CAS  PubMed  Google Scholar 

  19. Ogawa S, Hosoi T, Shiraki M, Orimo H, Emi M, Muramatsu M, Ouchi Y, Inoue S (2000) Association of estrogen receptor beta gene polymorphism with bone mineral density. Biochem Biophys Res Commun 269(2):537–541. doi:10.1006/bbrc.2000.2285

    Article  CAS  PubMed  Google Scholar 

  20. Forsti A, Zhao C, Israelsson E, Dahlman-Wright K, Gustafsson JA, Hemminki K (2003) Polymorphisms in the estrogen receptor beta gene and risk of breast cancer: no association. Breast Cancer Res Treat 79(3):409–413

    Article  PubMed  Google Scholar 

  21. Maguire P, Margolin S, Skoglund J, Sun XF, Gustafsson JA, Borresen-Dale AL, Lindblom A (2005) Estrogen receptor beta (ESR2) polymorphisms in familial and sporadic breast cancer. Breast Cancer Res Treat 94(2):145–152. doi:10.1007/s10549-005-7697-7

    Article  CAS  PubMed  Google Scholar 

  22. Thellenberg-Karlsson C, Lindstrom S, Malmer B, Wiklund F, Augustsson-Balter K, Adami HO, Stattin P, Nilsson M, Dahlman-Wright K, Gustafsson JA, Gronberg H (2006) Estrogen receptor beta polymorphism is associated with prostate cancer risk. Clin Cancer Res 12(6):1936–1941. doi:10.1158/1078-0432.CCR-05-0269 (An official journal of the American Association for Cancer Research)

    Article  CAS  PubMed  Google Scholar 

  23. Ashton KA, Proietto A, Otton G, Symonds I, McEvoy M, Attia J, Gilbert M, Hamann U, Scott RJ (2009) Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG Int J Obstet Gynaecol 116(8):1053–1061. doi:10.1111/j.1471-0528.2009.02185.x

    Article  CAS  Google Scholar 

  24. Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I (2004) Estrogen receptor beta (ESR2) polymorphisms and endometrial cancer (United States). Cancer Causes Control 15(6):627–633. doi:10.1023/B:CACO.0000036170.28502.5f

    Article  PubMed  Google Scholar 

  25. Li LC, Yeh CC, Nojima D, Dahiya R (2000) Cloning and characterization of human estrogen receptor beta promoter. Biochem Biophys Res Commun 275(2):682–689. doi:10.1006/bbrc.2000.3363

    Article  CAS  PubMed  Google Scholar 

  26. Lee JH, Kim Y, Choi JW, Kim YS (2013) Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis. Arch Med Res. doi:10.1016/j.arcmed.2012.12.002

    Google Scholar 

  27. Chen J, Liu RY, Yang L, Zhao J, Zhao X, Lu D, Yi N, Han B, Chen XF, Zhang K, He J, Lei Z, Zhou Y, Pasche B, Li X, Zhang HT (2012) A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk. J Cancer Res Clin Oncol 139(2):231–242. doi:10.1007/s00432-012-1314-z

    Article  PubMed  Google Scholar 

  28. Braunagel D, Schaich M, Kramer M, Dransfeld CL, Ehninger G, Mahlknech U (2011) A NME1 promoter SNP predicts Ara-C associated neurotoxicity in AML patients. Leuk Lymphoma. doi:10.3109/10428194.2011.610015

  29. Nicodemus KK, Law AJ, Luna A, Vakkalanka R, Straub RE, Kleinman JE, Weinberger DR (2009) A 5′ promoter region SNP in NRG1 is associated with schizophrenia risk and type III isoform expression. Mol Psychiatry 14(8):741–743. doi:10.1038/mp.2008.150

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Haring J, Schuler S, Lattrich C, Ortmann O, Treeck O (2012) Role of estrogen receptor beta in gynecological cancer. Gynecol Oncol 127(3):673–676. doi:10.1016/j.ygyno.2012.09.006

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank Helena Lowack for excellent technical assistance.

Conflict of interest

We declare that we have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University Medical Center Regensburg, 93053, Regensburg, Germany

    Claus Lattrich, Julia Häring, Susanne Schüler, Olaf Ortmann & Oliver Treeck

  2. Second Department of Gynecology, Medical University of Lublin, Lublin, Poland

    Maciej Skrzypczak

Authors
  1. Claus Lattrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia Häring
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susanne Schüler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maciej Skrzypczak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Olaf Ortmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Oliver Treeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claus Lattrich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lattrich, C., Häring, J., Schüler, S. et al. Polymorphisms in the promoter region of estrogen receptor β gene in endometrial cancer. Arch Gynecol Obstet 289, 631–635 (2014). https://doi.org/10.1007/s00404-013-3012-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-013-3012-8

Keywords

Search

Navigation